Monitor the upcoming Q4 2026 topline data readout from Part 3 of the Phase 1 trial for DA-1726, which is the next key catalyst. The CMO appointment adds relevant expertise but does not change the binary risk profile of the data readout.
Price Chart
Executive Summary
MetaVia Inc. appointed Sarah Kaplan Browne, M.D. as Chief Medical Officer, effective October 12, 2026. Dr. Browne brings extensive experience in liver and metabolic disease drug development, including dual GLP-1/glucagon receptor agonists, and her appointment comes ahead of the anticipated Q4 2026 topline data readout from Part 3 of the Phase 1 trial for DA-1726. This is a routine executive appointment with no financial data disclosed.
Key Facts
- Sarah Kaplan Browne, M.D. appointed Chief Medical Officer effective October 12, 2026.
- Dr. Browne has over 20 years of experience in clinical development and regulatory science.
- She previously led clinical development of pemvidutide (dual GLP-1/glucagon receptor agonist) at Altimmune through Phase 2 and End-of-Phase 2 FDA meeting.
- MetaVia anticipates Q4 2026 topline data from Part 3 of Phase 1 trial for DA-1726 (evaluating 48 mg and 64 mg doses).
- Dr. Browne also served at FDA's CBER as Senior Advisor for Clinical Review.
Financial Impact
No financial impact disclosed; executive appointment with no material financial terms.
Risk Factors
- Phase 1 Part 3 data for DA-1726 may not meet efficacy or safety endpoints.
- Clinical-stage biotech with no approved products; reliance on pipeline success.
- Potential need for additional capital to fund ongoing development.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-115300 |
| Document: mtva-ex99d1.htm | 0001104659-26-115300 |
| Document: 0001104659-26-115300-index-headers.html | 0001104659-26-115300 |
| Document: 0001104659-26-115300-index.html | 0001104659-26-115300 |
| Document: 0001104659-26-115300.txt | 0001104659-26-115300 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 3 | $1.36 | awaiting T+20 | — | $1.22 (−10.66%) |
Oct 13, 2026 13d ago | 8-K | $1.43 | awaiting T+20 | — | $1.22 (−15.03%) |
Sep 9, 2026 6w ago | 8-K | $1.74 $1.46 | ▼ −16.09% | ▼ −18.04% | $1.22 (−30.17%) |
Jul 9, 2026 15w ago | 8-K | $1.73 $1.45 | ▼ −16.18% | ▼ −18.43% | $1.22 (−29.77%) |
Jul 2, 2026 16w ago | 424B5 | $1.48 $1.44 | ▲ +2.70% | ▲ +2.29% | $1.22 (+17.91%) |
Jun 8, 2026 20w ago | 8-K | $1.89 $1.58 | ▼ −16.40% | ▼ −17.85% | $1.22 (−35.71%) |
Jun 8, 2026 20w ago | 8-K | $2.22 $1.51 | ▼ −31.98% | ▼ −33.61% | $1.22 (−45.27%) |
May 27, 2026 21w ago | 8-K | $3.34 $1.53 | ▼ −54.19% | ▼ −52.29% | $1.22 (−63.62%) |
May 18, 2026 23w ago | 8-K | $1.11 $1.65 | ▲ +48.65% | ▲ +47.07% | $1.22 (+9.46%) |
May 14, 2026 23w ago | 8-K | $1.11 $1.71 | ▲ +54.05% | ▲ +51.94% | $1.22 (+9.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers